Neuronetics ( (STIM) ) has released its Q4 earnings. Here is a breakdown of the information Neuronetics presented to its investors.
Neuronetics, Inc., a medical technology company, specializes in neurohealth therapies, offering non-drug treatments for mental health conditions, particularly through its NeuroStar Advanced Therapy System. In its latest earnings report, Neuronetics highlighted a transformative year marked by strategic acquisitions and financial growth. The company reported a 5% increase in full-year revenue for 2024, reaching $74.9 million, and an 11% increase in fourth-quarter revenue compared to the previous year. Key achievements include the acquisition of Greenbrook TMS, which contributed to a significant rise in U.S. clinic revenue, and FDA clearance for treating adolescents with depression. Despite these advancements, the company faced challenges, including a decrease in gross margin and an increased net loss due to acquisition-related expenses. Looking forward, Neuronetics aims to achieve double-digit revenue growth and become cash flow positive by the third quarter of 2025, leveraging its expanded network and strategic initiatives.